Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Common Stock, par value $0.0001 | Options Exercise | $334 | +139 | +0.79% | $2.40 | 17.8K | Dec 14, 2021 | Direct | |
holding | ALT | Common Stock, par value $0.0001 | 333 | Dec 14, 2021 | See Footnote | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ALT | Stock Options (option to buy) | Options Exercise | $0 | -139 | -100% | $0.00* | 0 | Dec 14, 2021 | Common Stock, par value $0.0001 | 139 | $2.40 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President. |
F2 | This option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split reverse stock split that occurred on September 13, 2018. |
F3 | This option is fully vested and exercisable as of the date hereof. |